866-997-4948(US-Canada Toll Free)

High Content Screening/Imaging: Technologies and Global Markets

Published By :

BCC Research

Published Date : Oct 2018

Category :


No. of Pages : 171 Pages


High content screening (HCS) is a technique that has been developed to collect quantitative data from cell populations. The market is growing at a CAGR of REDACTED and is expected to reach REDACTED in 2023, up from REDACTED in 2017. HCS systems allow relatively high throughput screening of cells, in which each cell in an array would be analyzed at a subcellular resolution using multicolored, fluorescence-based reagents for both specificity and sensitivity. The method is integrated with analytical tools such asmicroscopy, multiparameter image processing, and visualization tools. HCS integrates the instrumentation, application software, reagents, sample preparation, and informatics and bioinformatics required to rapidly flow from producing data, generating information, and ultimately creating new cellular knowledge. High content screening is increasingly being adopted in biological research and drug discovery. Additionally, it is being implemented in oncology, neuroscience, and oncology research, including primary compound screening and post-primary screening. Recently, high content approaches have been used extensively in stem cell biology.

The major factors contributing to the growth of the HCS market is the rising adoption of high content screening technology in research and development activities. The rapid adoption of HCS technology in the pharmaceutical industry and academic research center indicates the importance of this informationrich screening tool. The imaging of cell function has become increasingly important to understand the underlying functional biology associated with new therapeutic targets. Demand for improved technologies for cell research, government support and emergence of sophisticated informatics solutions, and rising demand for better screening systems is augmenting the demand for high content imaging within fully automated screening laboratories. Furthermore, technological advancements and developments in biological research and the discovery of more effective therapies for the treatment of human disease is fueling the growth of the market. HCS imaging systems have continually evolved with many improvements enabled to meet user demands of greater flexibility and the growing requirements of assays involving complex cellular disease models. Increasing drug discovery R&D globally, increasing investments and introduction of advanced imaging instruments are the other drivers for the HCS market.

The high cost of HCS instrumentation is the primary factor restraining the growth of the market. The price of machinery and instrumentation prohibits a small economy country or a research organization from purchasing HCS equipment. Companies are introducing more sensitive cameras and better light sources such as LED and multicolor illumination, which are increasing the output and reliability of the system and, therefore, the overall cost of the microscopes. The price of HCS equipment varies from a hundred thousand to a million, depending on the specifications. Inadequate infrastructure and less funding for R&D in emerging countries will also hinder the market as installation and maintenance costs
are also very high and not easily feasible for emerging economies.

Adoption of HCS in the analysis of 3D spheroids, microtissues and phenotypic assays, are expected to impact gene editing studies based on CRISPR-Cas9 in the future. Moreover, the growing availability of perturbagen libraries and HCS infrastructure within academic research centers has prompted widespread interest in HCS applications among academic investigators. The combination of HCS with chemical genetics, where small organic molecules are used to study biological systems has emerged as a powerful approach for defining protein functions and dissecting signaling pathways. The rapid growth of genome-wide RNA interference (RNAi) technology to probe gene function in mammalian cell culture systematically have popularized HCS systems in academic research environments."

"Report Scope

The HCS/I market has significant potential due to rising demand from the drug discovery and molecular diagnosis segments. The capabilities and possibilities of HCS/I market growth increases with the growth of new technologies and technological advancements. Emerging economies such as China, India, and South Korea are considered to be lucrative regions that are creating ample opportunities and scope for the market. Investments and funding from government and private ventures, research institutes and universities are supporting exploration into the potential of this market. Growing drug discovery and molecular diagnostic and research through HCS/I will further boost the market in the near future. The global rise in infectious and noninfectious diseases, growing populations, technological advancements and innovation are other factors creating considerable demand for HCS/I.

The scope of this study encompasses the current market for drug discovery, molecular diagnostics, cancer research, personalized medicine and compound profiling. The report also includes regulatory aspects, recent developments, market projections, competitive landscapes and market share. Analyses of patents, clinical trials, innovations and opportunities, as well as the latest trends, are also discussed in the report. The report intends to explain the key trends of HCS/I technologies and applications in various geographies. It also discusses the market determinants that act as motivating and restraining factors and provides insights to stakeholders and potential entrants. The report will be a key decision-making tool for government organizations, researchers, private players, angel investors, potential entrants and so forth.

Report Includes:

- 38 data tables and 23 additional tables
- An overview of the global markets for high content screening/imaging technologies
- Analyses of global market trends, with data from 2017, estimated from 2018 and projections of compound annual growth rates (CAGRs) through 2023
- Coverage of various microscope and imaging technologies in the industry
- Detailed analysis of the technological advancement in cytometers, light sources, detectors/sensors and liquid handling instruments
- Discussion of the various market motivators i.e. increasing R&D budget, advantages over manual and HTS, technological advancement, and automation
- Company profiles of major players in the industry, including Albany Molecular Research, Inc. (AMRI), Cell Signaling Technology, Danaher Corp., GE Healthcare and Instrument Systems"
Table of Contents
Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Intended Audience
Scope of Report
Information Sources
Research Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
Overview of Microscope and Imaging Technologies
Scanning Probe Microscopy
Scanning Electron Microscope
Transmission Electron Microscopy
Technological Advancements
Liquid Handling Instruments
Process Overview
High Content Screening
High Throughput Screening (HTS)
Market Dynamics
Key Factors Driving the Market
Limitations and Challenges
Market Opportunities
Chapter 4 Market Breakdown by Component
Instrument or Platform
Imaging Device
Plate Reader
Light Sources
Liquid Handling Instruments
Consumables (Reagents and Kits)
Software and Analytics
Store Image and Database Management Software by Thermo Fisher Scientific
OpenHiCAMM (Open Hi Content Acquisition for Manager) Software
siRNA Screens
Chapter 5 Market Breakdown by End User
Laboratories and Pathology Centers
Companies (Biotechnology, Pharmaceutical and CRO)
Chapter 6 Market Breakdown by Application
Molecular Diagnosis
Drug Discovery
Toxicity Studies
Acute Toxicity Studies
Subchronic Toxicity Studies
Chronic Toxicity
Compound Profiling
Chapter 7 Market Breakdown by Region
North America
United States
The U.K.
Rest of Europe
MEA (Middle East and Africa)
Rest of Asia-Pacific
Rest of the World
Chapter 8 Patent Review
Chapter 9 Industry Structure
Thermo Fisher Scientific
GE Healthcare
GE Healthcare Patents, 2015-2017
Olympus Corp.
Molecular Devices
PerkinElmer, Inc.
Chapter 10 Company Profiles

List of Table

List of Tables
Summary Table : Global Market for High Content Screening/Imaging, by Component, Through 2023
Table 1 : Microscopes Used in HCS/I
Table 2 : HTS Detection Methods
Table 3 : HTS Product Portfolios
Table 4 : Comparison of Cellomics with Other Omics Techniques
Table 5 : Comparison of HCS Microscopes
Table 6 : Global Market for HCS/I, by Component, Through 2023
Table 7 : Global Market for HCS/I, by Instrument/Platform, Through 2023
Table 8 : Global Market for Instruments/Platforms, by Region, Through 2023
Table 9 : HCS Platforms, by Thermo Fisher Scientific
Table 10 : Cytometers
Table 11 : Microplate Readers Available in the Market and Their Manufacturers
Table 12 : Fluorescent Dyes Used for the Sensor Array
Table 13 : Automated Liquid Handling Modules
Table 14 : Global Market for Consumables, by Region, Through 2023
Table 15 : Specification of HCS Live/Dead Green Kit
Table 16 : Global Market for Software and Analytics, by Region, Through 2023
Table 17 : Global Market for Services, by Region, Through 2023
Table 18 : Global Market for HCS/I, by End User, Through 2023
Table 19 : Global Market for HCS/I in Academics, by Region, Through 2023
Table 20 : Institutes with HCS Facilities
Table 21 : Global Market for HCS/I in Laboratories and Pathology Centers, by Region, Through 2023
Table 22 : Global Market for HCS/I Used by Companies, by Region, Through 2023
Table 23 : Global Market for HCS/I, by Application, Through 2023
Table 24 : Global Market for HCS/I, by Region, Through 2023
Table 25 : Global Market for HCS/I in Molecular Diagnostics, by Region, Through 2023
Table 26 : Global Market for HCS/I in Oncology, by Region, Through 2023
Table 27 : Global Market for HCS/I in Drug Discovery, by Region, Through 2023
Table 28 : Evotec Products in Development for Cancer in Various Stages of Research
Table 29 : Global Market for HCS/I in Toxicity, by Region, Through 2023
Table 30 : Global Market for HCS/I in Neuroscience, by Region, Through 2023
Table 31 : Global Market for HCS/I in Compound Profiling, by Region, Through 2023
Table 32 : North American Market for HCS/I, by Country, Through 2023
Table 33 : North American Market for HCS/I, by Component, Through 2023
Table 34 : North American Market for HCS/I, by End User, Through 2023
Table 35 : North American Market for HCS/I, by Application, Through 2023
Table 36 : Total Pharma Business R&D Expenditures in Canada, 2011-2015
Table 37 : European Market for HCS/I, by Country, Through 2023
Table 38 : European Market for HCS/I, by Component, Through 2023
Table 39 : European Market for HCS/I, by End User, Through 2023
Table 40 : European Market for HCS/I, by Application, Through 2023
Table 41 : Asia-Pacific Market for HCS/I, by Country, Through 2023
Table 42 : Asia-Pacific Market for HCS/I, by Component, Through 2023
Table 43 : Asia-Pacific Market for HCS/I, by End User, Through 2023
Table 44 : Asia-Pacific Market for HCS/I, by Application, Through 2023
Table 45 : Vaccine Manufacturers in India
Table 46 : ROW Market for HCS/I, by Component, Through 2023
Table 47 : ROW Market for HCS/I, by End User, Through 2023
Table 48 : ROW Market for HCS/I, by Application, Through 2023
Table 49 : Number of Patents Issued, by Key Company/Assignee, January 2015, Through 2017
Table 50 : Number of Patents Issued, by Category, 2015-2017
Table 51 : Number of Patents Issued, by Country, 2015-2017
Table 52 : Number of Patents Issued, by Publication Year, 2015-2017
Table 53 : Patents Issued, January 2015-December 2017
Table 54 : Thermo Fisher Scientific Products Covered One or More Patents
Table 55 : GE Healthcare Patents, 2015-2017
Table 56 : Molecular Devices Patents, 2015-2017
Table 57 : Recent Collaborations in the HCS Market, January 2016-February 2018
Table 58 : Recent Product Launches in the HCS Market, April 2015-March 2018
Table 59 : Major Partnerships in the HCS Market, 2017
Table 60 : Major Mergers and Acquisitions in the HCS Market, 2017

List of Chart

List of Figures
Summary Figure : Global Market for High Content Screening/Imaging, by Component, 2017-2023
Figure 1 : Approaches for Imaging Sample Surfaces
Figure 2 : HCS in Drug Discovery
Figure 3 : Four Steps of Data Analysis
Figure 4 : Basic Tools for High Content Screening
Figure 5 : Advantages of HTS
Figure 6 : Application of High-Throughput Screening
Figure 7 : Software Utilized for Data Analysis
Figure 8 : Flow of Funding for Disease Research, 2014-2016
Figure 9 : Investments, by Funding Category, 2016
Figure 10 : Technological Advancements in HCS
Figure 11 : Per Capita Healthcare Expenditures, 2016
Figure 12 : GDP Growth Rate of India and China, 2013-2016
Figure 13 : Key Benefits of Vectra Polaris Imaging Device
Figure 14 : Five Main Components of a Flow Cytometer
Figure 15 : Microplate Reader Categories
Figure 16 : Features of ThiolTracker Violet
Figure 17 : Features of HCS Studio 2.0 Cell Analysis Software
Figure 18 : Features of Store Image and Database Management Software
Figure 19 : Key Features of OpenHiCAMM
Figure 20 : OpenHiCAMM: High Content Screening Software for Complex Microscope Imaging Workflows
Figure 21 : Analysis of a Fluorescent Cellular Assay
Figure 22 : Some of the Companies Contributing to Research and Drug Discovery
Figure 23 : Incidence of Cancer in the U.S., 2017
Figure 24 : Drug Discovery Cycle
Figure 25 : Features of the Lead Compound
Figure 26 : Timeline of Drug Discovery and Development
Figure 27 : Types of Toxicity Studies
Figure 28 : Percentage of New Cases by Age Group: Brain and Other Nervous System Cancers
Figure 29 : Strategies to Improve Screening Using Compound Profiling
Figure 30 : Gross Domestic Spending on R&D in North American Countries, 2016
Figure 31 : U.S. Cancer Cases in Females, 2012
Figure 32 : U.S. Cancer Cases in Males, 2012
Figure 33 : Healthcare Expenditures for R&D, by U.S. State, 2016
Figure 34 : Prevalence of Viral Hepatitis in the U.S., 2015
Figure 35 : Gross Domestic Spending on Healthcare R&D in Canada, 2015 and 2016
Figure 36 : Leading Causes of Death in Canada, 2017
Figure 37 : Distribution of Projected Cancer Cases in Canada, by Type, 2017
Figure 38 : European Union Investments in R&D Funding for Neglected Diseases, 2013-2016
Figure 39 : Mortality from Cancer in the U.K., 2011-2017
Figure 40 : U.K. Investments in R&D Funding for Neglected Diseases 2013-2016
Figure 41 : Cancer Mortality in Germany, 2011-2017
Figure 42 : Germanys Spending on Neglected Diseases, 2013-2016
Figure 43 : Cancer Mortality in France, 2011-2017
Figure 44 : Products in Development, by Therapeutic Application, 2016
Figure 45 : French Spending on Neglected Diseases, 2013-2016
Figure 46 : Cancer Mortality in Spain, 2011-2017
Figure 47 : Spains Spending on Neglected Diseases, 2013-2016
Figure 48 : Cancer Mortality in Italy, 2011-2017
Figure 49 : European Countries with High Cancer Mortality, 2014
Figure 50 : Healthcare Expenditures in India
Figure 51 : Healthcare Expenditures in China, 2016
Figure 52 : Industry Structure of the High Content Screening Market
Figure 53 : Strategies Adopted, by Key Market Players

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *